Global Intravenous Iron Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2029

                                          
Global Intravenous Iron Drugs Market 2021: By product type (Iron dextran, Iron sucrose, Ferric carboxymaltose), By application (Chronic kidney disease (CKD), Inflammatory bowel disease (IBD), Cancer)

Global Intravenous Iron Drugs Market is a recent report generated by Trusted Business Insights. The study and analysis were administered using expert opinions and inputs, as well as thorough primary and secondary research efforts to determine various aspects of the intravenous iron drugs market. The market segmentation allows for deeper thought and understanding in order to strongly assess, analyze, and study. Besides revenues for segments, the global, regional, and country-wise market revenue segmentation has been compiled in a veracious manner for clear understanding and flow.

The Global Intravenous Iron Drugs market size was valued at USD $2.3 Billion in 2020, USD $2.5 Billion in 2021, forecasted to reach  USD $2.71 Billion in 2022, and is projected to reach USD $5.2 Billion by 2030, and is anticipated to expand at a CAGR of 8.5% over the forecast period from 2020 to 2030.

Overview:

A vital component of hemoglobin, iron plays a key role in transporting oxygen throughout our bodies. Iron infusion is a procedure by which iron is intravenously (delivered to the body through the veins) administered to a person. The method by which this is delivered is known as an IV or intravenous infusion. This is done by doctors for patients that are unable to consume iron supplements either – orally, cant adequately absorb it through the gut, lack of iron due to loss of blood, or by those that need to increase their iron levels quickly to avoid medical complications. It is usually prescribed to treat iron deficiency anemia. It is known to be unsuitable for those in their first trimester and is usually more expensive than oral forms of therapy.

Dynamics:

The global intravenous iron drugs market is slated to grow at a high CAGR over the forecast time period from its valuation of $US 1.63 billion in 2018. The reasons for this growth have been linked to the increasing number of dialysis patients, a surge in chronic kidney disease patients and the rising geriatric population.

Additionally, increased healthcare investments, higher medical expenditures, and an escalating number of iron deficiency anemia cases will aid the growth of this market.
A few considerable side-effects are – muscle cramps, nausea, vomiting, coughing, and joint & back pain as well as constipation. These various related side-effects and stringent guidelines imposed by the respective authorities may hamper the growth of the global intravenous iron drugs market.

The process of approval and the requirement to comply with several regulations may hinder the expansion of this market.

On the basis of product type, this market is sectioned into – ferric carboxymaltose, iron dextran, iron sucrose as well as other products. Due to its increased application in drug discovery, reduced cost, and superior performance, the ferric carboxymaltose segment occupied the largest share of the market in 2018 and is expected to continue to do so over the forecast period.
The segment for iron sucrose had the second-largest share of the market, followed by products like ferumoxytol and ferric maltol.

In terms of application, the intravenous iron drugs market is segmented into chronic kidney disease (CKD), cancer and inflammatory bowel disease, among others. The largest market share in 2018 was accounted for by the chronic kidney disease segment. Some factors that are the cause of this are a general inclination towards a sedentary lifestyle and a growing geriatric population. The segment for cancer is slated to establish the quickest growth over the forecasted tenure due to its very high incidence rates.

Regional Analysis:

The global intravenous iron drugs market is extremely competitive thanks to the presence of established companies and the emergence of new ones. Large market shares in 2018 were held by Daiichi Sankyo Company, AMAG Pharmaceuticals, Vifor Pharma, and Pharmacosmos respectively. This was due to a wide geographical presence and an extensive product portfolio. Several strategies such as mergers & acquisitions, new product development, regional expansions, and strategic partnerships have been undertaken to achieve a competitive edge in the market.
Emerging markets like Japan, China, South Korea, and India are projected to achieve significant levels of growth during the forecast period.

Below are the leading companies profiled in this Intravenous Iron Drugs Market Report:

  
AbbVie Inc. (Allergan Plc)
  
Actavis Inc.
  
Allergan Inc.
  
AMAG Pharmaceuticals Inc.
  
American Regent Inc.
  
American Regent. Inc.
  
Daiichi Sankyo Company, Ltd. (American Regent. Inc.)
  
Fresenius Medical Care AG & Co. KGaA
  
Galenica Ltd.
  
Luitpold Pharmaceuticals Inc.
  
Pharmacosmos A/S
  
Rockwell Medical Technologies Inc.
  
Sanofi S.A.
  
Shield Therapeutics PLC
  
Vifor Pharma Ltd.
  
Vifor Pharma Management Ltd.

Global Intravenous Iron Drugs Market Segmentation:

By product type

  
Iron dextran
  
Iron sucrose
  
Ferric carboxymaltose

By application

  
Chronic kidney disease (CKD)
  
Inflammatory bowel disease (IBD)
  
Cancer
This research comprehensively answers the following 9 important questions:

  
Q.1. What are some of the most promising growth trends in the Intravenous Iron Drugs market worldwide?
  
Q.2.Which segments and sub-segments will grow at a faster pace and why? Which segment is nearing the peak and demand saturation?
  
Q.3.Which region will witness a higher growth rate and why? Which region might see a slower or negative growth region?
  
Q.4.What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Intravenous Iron Drugs market?
  
Q.5.What are the business risks and who pose challenges to the global leaders and are competitive threats in this Intravenous Iron Drugs market?
  
Q.6.What are the emerging trends post COVID-19 reshuffle in this Intravenous Iron Drugs market and the what are reasons behind these trends and do they translate in global exploration?
  
Q.7. Who are the major global and regional players in the Intravenous Iron Drugs market? Which are the strategic initiatives key players are pursuing for business growth?
  
Q.8.Which are the competing products in Intravenous Iron Drugs market and how big of a threat do they pose for loss of market share by material or product substitution?
  
Q.9.What M & A activity has occurred in the last 5 years and what is its impact on the Intravenous Iron Drugs industry?